Nuvalent, Inc. (NUVL)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Nuvalent, Inc. (NUVL)
Go deeper and ask any question about NUVL
Company Performance
Current Price
as of Oct 03, 2024$103.50
P/E Ratio
N/A
Market Cap
$6.66B
Description
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerNUVL
- Price$103.5-0.06%
Trading Information
- Market Cap$6.66B
- Float52.28%
- Average Daily Volume (1m)814,413
- Average Daily Volume (3m)473,836
- EPS-$2.78
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$57.17M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$65.15M
- EV$4.24B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account